Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects

A prospective randomized placebo-controlled double-blind cross-over study

Yasumasa Niwa, Masanao Nakamura, Ryoji Miyahara, Naoki Ohmiya, Osamu Watanabe, Takafumi Ando, Hiroki Kawashima, Akihiro Itoh, Yoshiki Hirooka, Hidemi Goto

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background and Aims: Little information is available regarding the prevention and treatment of small intestinal mucosal injuries caused by non-steroidal anti-inflammatory drugs (NSAIDs). We planned a pilot study to investigate the protective effects of geranylgeranylacetone (GGA) against NSAID-induced small intestinal injuries using video capsule endoscopy (VCE). Subjects and Methods: Ten healthy male volunteers took oral GGA 300 mg/day (regimen A) or placebo (regimen B) in addition to diclofenac 75 mg/day + rabeprazole 20 mg/day for 7 days. We conducted a cross-over trial of regimens A and B with a 2-week washout period. All subjects underwent VCE before and after each administration period, and were evaluated for NSAID-induced gastric and small intestinal mucosal lesions. Results: The number of mucosal lesions (erosions, ulcers and a red spot with possible bleeding) detected in both stomach and small bowel changed between prior to and immediately after administration period, with significantly fewer lesions for regimen A after administration period (mean ± SD A:B = 2.6 ± 3.2:9.5 ± 8.5; p = 0.027). Conclusions: Combination therapy with GGA and rabeprazole reduced the incidence of gastroenteropathy induced by 1-week administration of diclofenac. Our findings suggest this therapy as a candidate for protecting patients on long-term NSAID therapy.

Original languageEnglish
Pages (from-to)260-266
Number of pages7
JournalDigestion
Volume80
Issue number4
DOIs
Publication statusPublished - 01-12-2009
Externally publishedYes

Fingerprint

geranylgeranylacetone
Diclofenac
Cross-Over Studies
Stomach
Healthy Volunteers
Anti-Inflammatory Agents
Rabeprazole
Placebos
Capsule Endoscopy
Wounds and Injuries
Gastrointestinal Agents
Pharmaceutical Preparations
Ulcer
Therapeutics
Hemorrhage
Drug Therapy
Incidence

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Niwa, Yasumasa ; Nakamura, Masanao ; Miyahara, Ryoji ; Ohmiya, Naoki ; Watanabe, Osamu ; Ando, Takafumi ; Kawashima, Hiroki ; Itoh, Akihiro ; Hirooka, Yoshiki ; Goto, Hidemi. / Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects : A prospective randomized placebo-controlled double-blind cross-over study. In: Digestion. 2009 ; Vol. 80, No. 4. pp. 260-266.
@article{814d48626a0f4146884eaa805053fde8,
title = "Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects: A prospective randomized placebo-controlled double-blind cross-over study",
abstract = "Background and Aims: Little information is available regarding the prevention and treatment of small intestinal mucosal injuries caused by non-steroidal anti-inflammatory drugs (NSAIDs). We planned a pilot study to investigate the protective effects of geranylgeranylacetone (GGA) against NSAID-induced small intestinal injuries using video capsule endoscopy (VCE). Subjects and Methods: Ten healthy male volunteers took oral GGA 300 mg/day (regimen A) or placebo (regimen B) in addition to diclofenac 75 mg/day + rabeprazole 20 mg/day for 7 days. We conducted a cross-over trial of regimens A and B with a 2-week washout period. All subjects underwent VCE before and after each administration period, and were evaluated for NSAID-induced gastric and small intestinal mucosal lesions. Results: The number of mucosal lesions (erosions, ulcers and a red spot with possible bleeding) detected in both stomach and small bowel changed between prior to and immediately after administration period, with significantly fewer lesions for regimen A after administration period (mean ± SD A:B = 2.6 ± 3.2:9.5 ± 8.5; p = 0.027). Conclusions: Combination therapy with GGA and rabeprazole reduced the incidence of gastroenteropathy induced by 1-week administration of diclofenac. Our findings suggest this therapy as a candidate for protecting patients on long-term NSAID therapy.",
author = "Yasumasa Niwa and Masanao Nakamura and Ryoji Miyahara and Naoki Ohmiya and Osamu Watanabe and Takafumi Ando and Hiroki Kawashima and Akihiro Itoh and Yoshiki Hirooka and Hidemi Goto",
year = "2009",
month = "12",
day = "1",
doi = "10.1159/000236032",
language = "English",
volume = "80",
pages = "260--266",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "4",

}

Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects : A prospective randomized placebo-controlled double-blind cross-over study. / Niwa, Yasumasa; Nakamura, Masanao; Miyahara, Ryoji; Ohmiya, Naoki; Watanabe, Osamu; Ando, Takafumi; Kawashima, Hiroki; Itoh, Akihiro; Hirooka, Yoshiki; Goto, Hidemi.

In: Digestion, Vol. 80, No. 4, 01.12.2009, p. 260-266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Geranylgeranylacetone protects against diclofenac-induced gastric and small intestinal mucosal injuries in healthy subjects

T2 - A prospective randomized placebo-controlled double-blind cross-over study

AU - Niwa, Yasumasa

AU - Nakamura, Masanao

AU - Miyahara, Ryoji

AU - Ohmiya, Naoki

AU - Watanabe, Osamu

AU - Ando, Takafumi

AU - Kawashima, Hiroki

AU - Itoh, Akihiro

AU - Hirooka, Yoshiki

AU - Goto, Hidemi

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background and Aims: Little information is available regarding the prevention and treatment of small intestinal mucosal injuries caused by non-steroidal anti-inflammatory drugs (NSAIDs). We planned a pilot study to investigate the protective effects of geranylgeranylacetone (GGA) against NSAID-induced small intestinal injuries using video capsule endoscopy (VCE). Subjects and Methods: Ten healthy male volunteers took oral GGA 300 mg/day (regimen A) or placebo (regimen B) in addition to diclofenac 75 mg/day + rabeprazole 20 mg/day for 7 days. We conducted a cross-over trial of regimens A and B with a 2-week washout period. All subjects underwent VCE before and after each administration period, and were evaluated for NSAID-induced gastric and small intestinal mucosal lesions. Results: The number of mucosal lesions (erosions, ulcers and a red spot with possible bleeding) detected in both stomach and small bowel changed between prior to and immediately after administration period, with significantly fewer lesions for regimen A after administration period (mean ± SD A:B = 2.6 ± 3.2:9.5 ± 8.5; p = 0.027). Conclusions: Combination therapy with GGA and rabeprazole reduced the incidence of gastroenteropathy induced by 1-week administration of diclofenac. Our findings suggest this therapy as a candidate for protecting patients on long-term NSAID therapy.

AB - Background and Aims: Little information is available regarding the prevention and treatment of small intestinal mucosal injuries caused by non-steroidal anti-inflammatory drugs (NSAIDs). We planned a pilot study to investigate the protective effects of geranylgeranylacetone (GGA) against NSAID-induced small intestinal injuries using video capsule endoscopy (VCE). Subjects and Methods: Ten healthy male volunteers took oral GGA 300 mg/day (regimen A) or placebo (regimen B) in addition to diclofenac 75 mg/day + rabeprazole 20 mg/day for 7 days. We conducted a cross-over trial of regimens A and B with a 2-week washout period. All subjects underwent VCE before and after each administration period, and were evaluated for NSAID-induced gastric and small intestinal mucosal lesions. Results: The number of mucosal lesions (erosions, ulcers and a red spot with possible bleeding) detected in both stomach and small bowel changed between prior to and immediately after administration period, with significantly fewer lesions for regimen A after administration period (mean ± SD A:B = 2.6 ± 3.2:9.5 ± 8.5; p = 0.027). Conclusions: Combination therapy with GGA and rabeprazole reduced the incidence of gastroenteropathy induced by 1-week administration of diclofenac. Our findings suggest this therapy as a candidate for protecting patients on long-term NSAID therapy.

UR - http://www.scopus.com/inward/record.url?scp=70350059067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350059067&partnerID=8YFLogxK

U2 - 10.1159/000236032

DO - 10.1159/000236032

M3 - Article

VL - 80

SP - 260

EP - 266

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 4

ER -